scholarly journals Effect of Recombinant Human Parathyroid Hormone (1-84) on Resolution of Active Charcot Neuro-osteoarthropathy in Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study

Diabetes Care ◽  
2021 ◽  
pp. dc210008
Author(s):  
Nina L. Petrova ◽  
Nicholas K. Donaldson ◽  
Maureen Bates ◽  
Wegin Tang ◽  
Timothy Jemmott ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Controlled Study ◽  
Human Parathyroid Hormone ◽  
Double Blind ◽  
Double Blind Placebo

Teriparatide (recombinant human parathyroid hormone [1‐34]) increases foot bone remodeling in diabetic chronic Charcot neuroarthropathy: a randomized double‐blind placebo‐controlled study

2019 ◽  
Vol 11 (9) ◽  
pp. 703-710 ◽  
Author(s):  
Ashu Rastogi ◽  
Abhishek Hajela ◽  
Mahesh Prakash ◽  
Niranjan Khandelwal ◽  
Rajender Kumar ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Bone Remodeling ◽  
Controlled Study ◽  
Human Parathyroid Hormone ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Charcot Neuroarthropathy

scholarly journals Effect of Recombinant Human Parathyroid Hormone (1-84) on Resolution of Active Charcot Neuro-osteoarthropathy in Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study

2021 ◽  
Author(s):  
Nina L Petrova ◽  
Nicholas K. Donaldson ◽  
Maureen Bates ◽  
Wegin Tang ◽  
Timothy Jemmott ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Controlled Trial ◽  
Linear Regression Analysis ◽  
Controlled Study ◽  
X Rays ◽  
Human Parathyroid Hormone ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Significant Difference ◽  
Prolonged Immobilization

<b>Objectives</b>: Fractures in Charcot neuro-osteoarthropathy (CN) often fail to heal despite prolonged immobilization with below-knee casting. The aim of the study was to assess the efficacy of recombinant human parathyroid hormone (PTH) in reducing time to resolution of CN and healing of fractures. <p><b>Research Design and Methods</b>: People with diabetes and acute (active) Charcot foot were randomized (double-blind) to either full length PTH (1-84) or placebo therapy - both in addition to below-knee casting and Calcium and Vitamin D3 supplementation. The primary outcome was resolution of CN, defined as a skin foot temperature difference below 2°C at two consecutive monthly visits. </p> <p><b>Results:</b> Median time to resolution was 5 months (95% CI 4, 12) in intervention and 6 months (95% CI 2, 9) in control. There was no significant difference in time to resolution between the groups (mixed effects logistic regression; p=0.64). The hazard ratio of resolution was 0.84 (95% CI 0.41, 1.74), p=0.64 and the odds ratio of resolution by 12 months was 1.22 (0.90, 1.67), p=0.20 (intervention versus control). On linear regression analysis, there were no significant differences in the effect of treatment on fracture scores quantitated on magnetic resonance imaging <a>scans </a>(coef= 0.13; 95% CI -0.62, 0.88; p=0.73) and on foot and ankle X-rays (coef= 0.30; 95% CI -0.03, 0.63; p=0.07). </p> <p><b>Conclusions</b>: This double-blind placebo-controlled trial did not reduce time to resolution or enhance fracture healing of CN. There was no added benefit of daily intervention with PTH (1-84) to below-knee casting in achieving earlier resolution of CN. </p>

scholarly journals Effect of Recombinant Human Parathyroid Hormone (1-84) on Resolution of Active Charcot Neuro-osteoarthropathy in Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study

2021 ◽  
Author(s):  
Nina L Petrova ◽  
Nicholas K. Donaldson ◽  
Maureen Bates ◽  
Wegin Tang ◽  
Timothy Jemmott ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Controlled Trial ◽  
Linear Regression Analysis ◽  
Controlled Study ◽  
X Rays ◽  
Human Parathyroid Hormone ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Significant Difference ◽  
Prolonged Immobilization

<b>Objectives</b>: Fractures in Charcot neuro-osteoarthropathy (CN) often fail to heal despite prolonged immobilization with below-knee casting. The aim of the study was to assess the efficacy of recombinant human parathyroid hormone (PTH) in reducing time to resolution of CN and healing of fractures. <p><b>Research Design and Methods</b>: People with diabetes and acute (active) Charcot foot were randomized (double-blind) to either full length PTH (1-84) or placebo therapy - both in addition to below-knee casting and Calcium and Vitamin D3 supplementation. The primary outcome was resolution of CN, defined as a skin foot temperature difference below 2°C at two consecutive monthly visits. </p> <p><b>Results:</b> Median time to resolution was 5 months (95% CI 4, 12) in intervention and 6 months (95% CI 2, 9) in control. There was no significant difference in time to resolution between the groups (mixed effects logistic regression; p=0.64). The hazard ratio of resolution was 0.84 (95% CI 0.41, 1.74), p=0.64 and the odds ratio of resolution by 12 months was 1.22 (0.90, 1.67), p=0.20 (intervention versus control). On linear regression analysis, there were no significant differences in the effect of treatment on fracture scores quantitated on magnetic resonance imaging <a>scans </a>(coef= 0.13; 95% CI -0.62, 0.88; p=0.73) and on foot and ankle X-rays (coef= 0.30; 95% CI -0.03, 0.63; p=0.07). </p> <p><b>Conclusions</b>: This double-blind placebo-controlled trial did not reduce time to resolution or enhance fracture healing of CN. There was no added benefit of daily intervention with PTH (1-84) to below-knee casting in achieving earlier resolution of CN. </p>

scholarly journals Effect of Paricalcitol on Circulating Parathyroid Hormone in X-Linked Hypophosphatemia: A Randomized, Double-Blind, Placebo-Controlled Study

2014 ◽  
Vol 99 (9) ◽  
pp. 3103-3111 ◽  
Author(s):  
Thomas O. Carpenter ◽  
Elizabeth A. Olear ◽  
Jane H. Zhang ◽  
Bruce K. Ellis ◽  
Christine A. Simpson ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo

Oral Calcium Effectively Reduces Parathyroid Hormone Levels in Hemodialysis Patients: A Randomized Double-Blind Placebo-Controlled Study

Nephron ◽  
1993 ◽  
Vol 65 (3) ◽  
pp. 369-374 ◽  
Author(s):  
Martin Rudncki ◽  
Jette Højsted ◽  
Lars J. Petersen ◽  
Henrik A. Sørensen ◽  
Lars Hyldstrup ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Hemodialysis Patients ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Oral Calcium ◽  
Hormone Levels

scholarly journals The Effect of Vitamin C on Parathyroid Hormone in Patients on Hemodialysis With Secondary Hyperparathyroidism: A Double Blind, Placebo-Controlled Study

2013 ◽  
Vol 5 (5) ◽  
pp. 962-966 ◽  
Author(s):  
Vajihe Biniaz ◽  
Eghlim Nemati ◽  
Ali Tayebi ◽  
Mehdi Sadeghi Shermeh ◽  
Abbas Ebadi
Keyword(s):  
Parathyroid Hormone ◽  
Vitamin C ◽  
Secondary Hyperparathyroidism ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo

Efficacy and safety of recombinant human parathyroid hormone (1–84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study

2013 ◽  
Vol 1 (4) ◽  
pp. 275-283 ◽  
Author(s):  
Michael Mannstadt ◽  
Bart L Clarke ◽  
Tamara Vokes ◽  
Maria Luisa Brandi ◽  
Lakshminarayan Ranganath ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Efficacy And Safety ◽  
Human Parathyroid Hormone ◽  
Phase 3 ◽  
Double Blind ◽  
Double Blind Placebo

105: The Efficacy of Cernilton® in Patients with Chronic Pelvic Pain Syndrome (CP/CPPS) Type Nih IIIA: A Randomized, Prospective, Double-Blind, Placebo Controlled Study

2006 ◽  
Vol 175 (4S) ◽  
pp. 34-34 ◽  
Author(s):  
Henning Schneider ◽  
Martin Ludwig ◽  
Andreas Horstmann ◽  
Jörg Schnitker ◽  
Wolfgang Weidner
Keyword(s):  
Pelvic Pain ◽  
Chronic Pelvic Pain ◽  
Chronic Pelvic Pain Syndrome ◽  
Pain Syndrome ◽  
Controlled Study ◽  
Pelvic Pain Syndrome ◽  
Double Blind ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document